57 related articles for article (PubMed ID: 38625413)
1. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012883. PubMed ID: 29164600
[TBL] [Abstract][Full Text] [Related]
2. [(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment.
Syed YY; Deeks E
CNS Drugs; 2015 Jul; 29(7):605-13. PubMed ID: 26175116
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive quantification of
Holy EN; Li E; Bhattarai A; Fletcher E; Alfaro ER; Harvey DJ; Spencer BA; Cherry SR; DeCarli CS; Fan AP
EJNMMI Res; 2024 Apr; 14(1):39. PubMed ID: 38625413
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive quantification of
Holy EN; Li E; Bhattarai A; Fletcher E; Alfaro ER; Harvey DJ; Spencer BA; Cherry SR; DeCarli CS; Fan AP
Res Sq; 2023 Dec; ():. PubMed ID: 38234716
[TBL] [Abstract][Full Text] [Related]
5. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
[TBL] [Abstract][Full Text] [Related]
6. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
[TBL] [Abstract][Full Text] [Related]
7. Patlak plot based on the first 30 minutes post-injection dynamic
Oliveira FP; Ferreira SM; Silva MG; Castanheira JC; Teixeira RJ; Costa DC
Br J Radiol; 2022 Oct; 95(1139):20211023. PubMed ID: 36069339
[TBL] [Abstract][Full Text] [Related]
8. Validation of Noninvasive Tracer Kinetic Analysis of
Bullich S; Barthel H; Koglin N; Becker GA; De Santi S; Jovalekic A; Stephens AW; Sabri O
J Nucl Med; 2018 Jul; 59(7):1104-1110. PubMed ID: 29175981
[TBL] [Abstract][Full Text] [Related]
9. An update on the use of image-derived input functions for human PET studies: new hopes or old illusions?
Volpi T; Maccioni L; Colpo M; Debiasi G; Capotosti A; Ciceri T; Carson RE; DeLorenzo C; Hahn A; Knudsen GM; Lammertsma AA; Price JC; Sossi V; Wang G; Zanotti-Fregonara P; Bertoldo A; Veronese M
EJNMMI Res; 2023 Nov; 13(1):97. PubMed ID: 37947880
[TBL] [Abstract][Full Text] [Related]
10. Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals.
Ebenau JL; Visser D; Verfaillie SCJ; Timmers T; van Leeuwenstijn MSSA; Kate MT; Windhorst AD; Barkhof F; Scheltens P; Prins ND; Boellaard R; van der Flier WM; van Berckel BNM
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):410-422. PubMed ID: 36071221
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients.
Bartelink IH; van de Stadt EA; Leeuwerik AF; Thijssen VLJL; Hupsel JRI; van den Nieuwendijk JF; Bahce I; Yaqub M; Hendrikse NH
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890095
[TBL] [Abstract][Full Text] [Related]
12. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report.
Delrieu J; Bateman RJ; Touchon J; Sabbagh M; Cummings J
J Prev Alzheimers Dis; 2022; 9(3):393-399. PubMed ID: 35841240
[TBL] [Abstract][Full Text] [Related]
13. Quantification of amyloid PET for future clinical use: a state-of-the-art review.
Pemberton HG; Collij LE; Heeman F; Bollack A; Shekari M; Salvadó G; Alves IL; Garcia DV; Battle M; Buckley C; Stephens AW; Bullich S; Garibotto V; Barkhof F; Gispert JD; Farrar G;
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3508-3528. PubMed ID: 35389071
[TBL] [Abstract][Full Text] [Related]
14. Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling.
Wang G; Nardo L; Parikh M; Abdelhafez YG; Li E; Spencer BA; Qi J; Jones T; Cherry SR; Badawi RD
J Nucl Med; 2022 Aug; 63(8):1274-1281. PubMed ID: 34795014
[TBL] [Abstract][Full Text] [Related]
15. PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research.
Bao W; Xie F; Zuo C; Guan Y; Huang YH
Front Aging Neurosci; 2021; 13():624330. PubMed ID: 34025386
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
